Grace Therapeutics (GRCE) Cash & Equivalents (2017 - 2026)
Grace Therapeutics (GRCE) posted Cash & Equivalents of $15.7 million for Q1 2026, down 10.38% sequentially from $17.5 million in Q4 2025, and down 26.44% YoY from $21.3 million in Q1 2025.
Grace Therapeutics (GRCE) Cash & Equivalents (2017 - 2026) Analysis & Trends
Grace Therapeutics has reported Cash & Equivalents for 10 years, with the latest figure at $15.7 million in Q1 2026.
- Quarterly Cash & Equivalents fell 26.44% year-over-year to $15.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.7 million (down 26.44% YoY) and the FY2026 annual result came in at $15.7 million, down 26.44% from the prior year.
- Cash & Equivalents retreated to $15.7 million in Q1 2026 per GRCE's latest filing, from $17.5 million in the prior quarter.
- Over five years, Cash & Equivalents peaked at $30.3 million in Q1 2022 and troughed at $10.1 million in Q1 2023.
- A 5-year average of $17.0 million and a median of $16.4 million in 2023 frame the typical range for Cash & Equivalents.
- The sharpest annual moves came in 2022 and 2023: Cash & Equivalents surged 142.01% in 2022, then sank 66.8% in 2023.
- Over 5 years, Cash & Equivalents stood at $30.3 million in 2022, then tumbled by 45.66% to $16.5 million in 2023, then slumped by 38.01% to $10.2 million in 2024, then jumped by 71.1% to $17.5 million in 2025, then dropped by 10.38% to $15.7 million in 2026.
- According to Business Quant data, Cash & Equivalents over the past three periods registered $15.7 million, $17.5 million, and $15.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 3.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.72 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.71 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 8.93 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 544.80 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 811.99 Mn |
| 10 | Grace Therapeutics | 37.99 Mn | 37.99 Mn | - | 13.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.76 Mn |
| Mar 31, 2026 | 15.67 Mn |
| Dec 31, 2025 | 17.49 Mn |
| Sep 30, 2025 | 14.97 Mn |
| Jun 30, 2025 | 18.09 Mn |
| Mar 31, 2025 | 21.30 Mn |
| Dec 31, 2024 | 10.22 Mn |
| Sep 30, 2024 | 14.14 Mn |
| Jun 30, 2024 | 16.35 Mn |
| Mar 31, 2024 | 19.73 Mn |
| Dec 31, 2023 | 16.49 Mn |
| Sep 30, 2023 | 16.40 Mn |
| Jun 30, 2023 | 16.22 Mn |
| Mar 31, 2023 | 10.07 Mn |
| Mar 31, 2022 | 30.34 Mn |
| Mar 31, 2021 | 12.54 Mn |
| Dec 31, 2020 | 19.44 Mn |
| Sep 30, 2020 | 5.49 Mn |
| Jun 30, 2020 | 6.85 Mn |
| Mar 31, 2020 | 14.24 Mn |